Salaita Khalid

Salaita Khalid is a prominent inventor based in Decatur, GA (US). He has made significant contributions to the field of therapeutic nucleic acids, holding 2 patents that focus on innovative approaches to medical treatment.

Latest Patents

Khalid's latest patents include groundbreaking work on particle-nucleic acid conjugates and their therapeutic uses. This disclosure relates to particles that are conjugated to therapeutic nucleic acids. In certain embodiments, the nucleic acid comprises a sequence that catalytically cleaves RNA, such as DNAzyme or RNAzyme. The particles may contain nucleic acids with both DNAzyme and/or RNAzyme and siRNA sequences. The cleaving nucleic acids can optionally include a sequence that hybridizes to a target of interest. Additionally, the particles may be conjugated to a targeting moiety. These conjugated particles have potential applications in the treatment or prevention of cancer, viral infections, and bacterial infections. They can also be utilized in detecting metal ions and other small molecule analytes.

Career Highlights

Salaita Khalid is affiliated with Emory University, where he continues to advance research in his field. His work has garnered attention for its innovative approach to addressing complex medical challenges.

Collaborations

Khalid collaborates with Kevin Yehl, contributing to the development of cutting-edge technologies in therapeutic applications.

Conclusion

Salaita Khalid's contributions to the field of therapeutic nucleic acids exemplify the impact of innovative research on healthcare. His patents reflect a commitment to advancing medical science and improving treatment options for various diseases.

Profile summary based on public USPTO records.